8-K
filed May 21, 2026, 2:10 PM ET
CIK 0002128772
other material
confidence high
sentiment neutral
materiality 0.50
Exeter Select Auto Receivables Trust 2026-1 issues $384.4M in ABS notes backed by sub-prime auto loans
Exeter Select Automobile Receivables Trust 2026-1
- Eight classes of notes issued: A-1 ($48M), A-2 ($97.43M), A-3 ($97.43M), B ($26.35M), C ($42.67M), D ($38.96M), E ($8.17M), N ($25.4M).
- Underwriting Agreement dated May 19, 2026 with Deutsche Bank, Citigroup, and Mizuho as representatives.
- Closing date on or about May 27, 2026; proceeds used to purchase sub-prime auto loan receivables from Exeter Finance LLC.
- Depositor EFCAR, LLC filed CEO certifications required by Form SF-3; exhibits include Indenture, Sale and Servicing Agreement, and Purchase Agreement.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0000929638-26-001947
- form_type
- 8-K
- ticker
- null
- cik
- 0002128772
- company_name
- Exeter Select Automobile Receivables Trust 2026-1
- filed_at
- 2026-05-21T18:10:15+00:00
- discovered_at
- 2026-05-21T18:11:00.290598+00:00
- generated_at
- 2026-05-21T18:13:16.949444+00:00
- sec_items
- ["1.01", "8.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0000929638-26-001947
- json_url
- https://secwatch.observer/filing/0000929638-26-001947.json
- markdown_url
- https://secwatch.observer/filing/0000929638-26-001947.md
- text_url
- https://secwatch.observer/filing/0000929638-26-001947.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/2128772/000092963826001947/0000929638-26-001947-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1654238/000092963826001947/esart2026-1_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
CPSH
CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share
CPS TECHNOLOGIES CORP/DE/
June 1, 2026, 9:35 AM ET
other_material
Items 1.01, 5.03, 8.01, 9.01
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CLIR
ClearSign Technologies prices 777,780-share public offering at $4.33/share for ~$3.37M gross proceeds
ClearSign Technologies Corp
June 1, 2026, 8:30 AM ET
other_material
Items 1.01, 8.01, 9.01
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
RDAC
Shareholders approve SPAC extension to Oct 15, 2027; ~1.9M shares redeemed
Rising Dragon Acquisition Corp.
June 1, 2026, 6:08 AM ET
other_material
Items 1.01, 5.03, 5.07, 8.01, 9.01
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
SYRE
Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030
Spyre Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ORKA
Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030
Oruka Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
VIASP
Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends
Via Renewables, Inc.
June 1, 2026, 3:06 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
BUKS
CEO Christopher Reedy discloses ongoing cancer treatment; remains in role
BUTLER NATIONAL CORP
June 1, 2026, 12:41 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ONCY
Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned
ONCOLYTICS BIOTECH INC
June 1, 2026, 9:06 AM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.